JP2014530220A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014530220A5 JP2014530220A5 JP2014534596A JP2014534596A JP2014530220A5 JP 2014530220 A5 JP2014530220 A5 JP 2014530220A5 JP 2014534596 A JP2014534596 A JP 2014534596A JP 2014534596 A JP2014534596 A JP 2014534596A JP 2014530220 A5 JP2014530220 A5 JP 2014530220A5
- Authority
- JP
- Japan
- Prior art keywords
- variant
- dyslipidemia
- obesity
- diabetes
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000032928 Dyslipidaemia Diseases 0.000 claims 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 claims 1
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 claims 1
- 101000846529 Homo sapiens Fibroblast growth factor 21 Proteins 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 102000056713 human FGF21 Human genes 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161542906P | 2011-10-04 | 2011-10-04 | |
| US61/542,906 | 2011-10-04 | ||
| PCT/US2012/057053 WO2013052311A1 (en) | 2011-10-04 | 2012-09-25 | Fibroblast growth factor 21 variants |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014530220A JP2014530220A (ja) | 2014-11-17 |
| JP2014530220A5 true JP2014530220A5 (OSRAM) | 2015-11-12 |
| JP6060167B2 JP6060167B2 (ja) | 2017-01-11 |
Family
ID=46964112
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014534596A Active JP6060167B2 (ja) | 2011-10-04 | 2012-09-25 | 線維芽細胞増殖因子２１変異体 |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US8541369B2 (OSRAM) |
| EP (1) | EP2763689B1 (OSRAM) |
| JP (1) | JP6060167B2 (OSRAM) |
| KR (1) | KR20140059271A (OSRAM) |
| CN (1) | CN103906530B (OSRAM) |
| AP (1) | AP2014007532A0 (OSRAM) |
| AR (1) | AR087973A1 (OSRAM) |
| AU (1) | AU2012318956A1 (OSRAM) |
| BR (1) | BR112014007532A2 (OSRAM) |
| CA (1) | CA2843520A1 (OSRAM) |
| CL (1) | CL2014000801A1 (OSRAM) |
| CO (1) | CO6910165A2 (OSRAM) |
| CR (1) | CR20140142A (OSRAM) |
| DO (1) | DOP2014000050A (OSRAM) |
| EA (1) | EA201490521A1 (OSRAM) |
| EC (1) | ECSP14013285A (OSRAM) |
| ES (1) | ES2548214T3 (OSRAM) |
| IL (1) | IL230754A0 (OSRAM) |
| IN (1) | IN2014CN00782A (OSRAM) |
| MA (1) | MA35458B1 (OSRAM) |
| MX (1) | MX2014004159A (OSRAM) |
| PE (1) | PE20142044A1 (OSRAM) |
| PH (1) | PH12014500740A1 (OSRAM) |
| SG (1) | SG11201401792UA (OSRAM) |
| TN (1) | TN2014000096A1 (OSRAM) |
| TW (1) | TWI461435B (OSRAM) |
| WO (1) | WO2013052311A1 (OSRAM) |
| ZA (1) | ZA201400882B (OSRAM) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010523084A (ja) | 2007-03-30 | 2010-07-15 | アンブルックス，インコーポレイテッド | 修飾ｆｇｆ−２１ポリペプチド |
| WO2013006486A2 (en) | 2011-07-01 | 2013-01-10 | Ngm Biopharmaceuticals, Inc. | Compositions, uses and methods for treatment of metabolic disorders and diseases |
| EA201491856A1 (ru) * | 2012-05-15 | 2015-03-31 | Эли Лилли Энд Компани | Терапевтическое применение белков фактора роста фибробластов 21 |
| TWI513705B (zh) | 2012-06-11 | 2015-12-21 | Lilly Co Eli | 纖維母細胞生長因子２１蛋白質 |
| CN104364261B (zh) | 2012-06-11 | 2017-04-05 | 伊莱利利公司 | 成纤维细胞生长因子21变体 |
| US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
| ES2828505T3 (es) | 2012-11-28 | 2021-05-26 | Ngm Biopharmaceuticals Inc | Composiciones y métodos para el tratamiento de trastornos y enfermedades metabólicos |
| SG10202100667SA (en) | 2012-12-27 | 2021-02-25 | Ngm Biopharmaceuticals Inc | Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| EP3062881B1 (en) | 2013-10-28 | 2019-10-02 | NGM Biopharmaceuticals, Inc. | Cancer models and associated methods |
| NZ722377A (en) | 2014-01-24 | 2022-09-30 | Ngm Biopharmaceuticals Inc | Binding proteins and methods of use thereof |
| WO2015138278A1 (en) | 2014-03-11 | 2015-09-17 | Novartis Ag | Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling |
| US10398758B2 (en) | 2014-05-28 | 2019-09-03 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions |
| US10456449B2 (en) | 2014-06-16 | 2019-10-29 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| CN107108711B (zh) | 2014-10-23 | 2021-11-23 | 恩格姆生物制药公司 | 包含肽变异体的药物组合物及其使用方法 |
| CN107108710B (zh) | 2014-10-24 | 2022-02-15 | 百时美施贵宝公司 | 修饰的fgf-21多肽及其用途 |
| WO2016073855A1 (en) | 2014-11-07 | 2016-05-12 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
| US10800843B2 (en) | 2015-07-29 | 2020-10-13 | Ngm Biopharmaceuticals, Inc. | Beta klotho-binding proteins |
| WO2017083276A1 (en) | 2015-11-09 | 2017-05-18 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders |
| TW201731867A (zh) * | 2015-12-02 | 2017-09-16 | 賽諾菲公司 | Ｆｇｆ２１變異體 |
| WO2017220706A1 (en) * | 2016-06-22 | 2017-12-28 | Novo Nordisk A/S | Pharmaceutical compositions of fgf21 derivatives and uses thereof |
| EP3503882A4 (en) | 2016-08-26 | 2020-07-29 | NGM Biopharmaceuticals, Inc. | METHOD FOR TREATING FIBROBLAST GROWTH FACTOR-19-MEDIATED CARCINOMAS AND TUMORS |
| CN106432509B (zh) * | 2016-09-13 | 2019-05-21 | 河南师范大学 | 一种治疗代谢疾病的重组人成纤维细胞生长因子21融合蛋白及其制备方法和应用 |
| CN106397607A (zh) * | 2016-09-13 | 2017-02-15 | 河南师范大学 | 重组人成纤维细胞生长因子21融合蛋白及其在制备治疗代谢疾病药物中的应用 |
| CN106220724B (zh) * | 2016-09-13 | 2019-10-11 | 河南师范大学 | 人成纤维细胞生长因子21重组蛋白及其制备方法和应用 |
| ES3014984T3 (en) | 2017-03-14 | 2025-04-28 | Sunshine Lake Pharma Co Ltd | Dual-target fusion proteins comprising the fc portion of an immunoglobulin |
| SG11202001379WA (en) | 2017-09-08 | 2020-03-30 | Bristol Myers Squibb Co | Modified fibroblast growth factor 21 (fgf-21) for use in methods for treating nonalcoholic steatohepatitis (nash) |
| CN119386161A (zh) | 2017-12-22 | 2025-02-07 | 诺华股份有限公司 | 用fgf21变体治疗代谢障碍的方法 |
| CN110128525B (zh) * | 2018-02-08 | 2022-08-26 | 广东东阳光药业有限公司 | Fgf21变体、融合蛋白及其应用 |
| KR20210027426A (ko) | 2018-07-03 | 2021-03-10 | 브리스톨-마이어스 스큅 컴퍼니 | Fgf21 제제 |
| CN109836486B (zh) * | 2019-01-30 | 2020-09-08 | 北京双因生物科技有限公司 | 成纤维生长因子21变体、其融合蛋白及其用途 |
| US20220064244A1 (en) * | 2019-03-05 | 2022-03-03 | Sunshine Lake Pharma Co., Ltd. | A polypeptide molecule and application thereof |
| CN114853908B (zh) | 2019-05-16 | 2024-06-07 | 浙江道尔生物科技有限公司 | 一种治疗代谢疾病的融合蛋白 |
| US20220016211A1 (en) | 2020-01-08 | 2022-01-20 | Bristol-Myers Squibb Company | Fgf-21 conjugate formulations |
| WO2021139744A1 (en) | 2020-01-11 | 2021-07-15 | Beijing Ql Biopharmaceutical Co., Ltd. | Conjugates of fusion proteins of glp-1 and fgf21 |
| WO2022032187A1 (en) | 2020-08-07 | 2022-02-10 | Bristol-Myers Squibb Company | Fgf21 combined with ccr2/5 antagonists for the treatment of fibrosis |
| KR102495299B1 (ko) * | 2020-11-03 | 2023-02-06 | 토드제약 주식회사 | Fgf21의 열탄력성을 이용한 fgf21 생산 방법 |
| US20240123031A1 (en) | 2020-11-25 | 2024-04-18 | Bristol-Myers Squibb Company | Methods of treating liver diseases |
| EP4288461A4 (en) | 2021-07-14 | 2025-07-02 | Beijing Ql Biopharmaceutical Co Ltd | FUSION POLYPEPTIDES FOR METABOLIC DISORDERS |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US7459540B1 (en) | 1999-09-07 | 2008-12-02 | Amgen Inc. | Fibroblast growth factor-like polypeptides |
| US20040259780A1 (en) | 2001-07-30 | 2004-12-23 | Glasebrook Andrew Lawrence | Method for treating diabetes and obesity |
| CA2549249A1 (en) * | 2003-12-10 | 2005-07-07 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
| US7622445B2 (en) | 2004-09-02 | 2009-11-24 | Eli Lilly And Company | Muteins of fibroblast growth factor 21 |
| ATE444307T1 (de) | 2004-09-02 | 2009-10-15 | Lilly Co Eli | Muteine des fibroblasten-wachstumsfaktors 21 |
| JP2010523084A (ja) | 2007-03-30 | 2010-07-15 | アンブルックス，インコーポレイテッド | 修飾ｆｇｆ−２１ポリペプチド |
| JOP20190083A1 (ar) * | 2008-06-04 | 2017-06-16 | Amgen Inc | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها |
| WO2010065439A1 (en) * | 2008-12-05 | 2010-06-10 | Eli Lilly And Company | Variants of fibroblast growth factor 21 |
| AU2010246038A1 (en) | 2009-05-05 | 2011-12-01 | Amgen Inc. | FGF21 mutants and uses thereof |
| BRPI1011404B1 (pt) | 2009-05-05 | 2022-05-03 | Amgen Inc | Polipeptídeos mutantes fgf21, polipeptídeo de fusão, multímero, composição farmacêutica, ácido nucleico isolado, vetor e célula hospedeira |
-
2012
- 2012-09-20 AR ARP120103466A patent/AR087973A1/es unknown
- 2012-09-21 TW TW101134800A patent/TWI461435B/zh not_active IP Right Cessation
- 2012-09-25 CA CA2843520A patent/CA2843520A1/en not_active Abandoned
- 2012-09-25 US US13/626,308 patent/US8541369B2/en active Active
- 2012-09-25 EA EA201490521A patent/EA201490521A1/ru unknown
- 2012-09-25 JP JP2014534596A patent/JP6060167B2/ja active Active
- 2012-09-25 SG SG11201401792UA patent/SG11201401792UA/en unknown
- 2012-09-25 PH PH1/2014/500740A patent/PH12014500740A1/en unknown
- 2012-09-25 PE PE2014000472A patent/PE20142044A1/es not_active Application Discontinuation
- 2012-09-25 MX MX2014004159A patent/MX2014004159A/es unknown
- 2012-09-25 EP EP12766847.3A patent/EP2763689B1/en active Active
- 2012-09-25 IN IN782CHN2014 patent/IN2014CN00782A/en unknown
- 2012-09-25 ES ES12766847.3T patent/ES2548214T3/es active Active
- 2012-09-25 BR BR112014007532A patent/BR112014007532A2/pt not_active IP Right Cessation
- 2012-09-25 WO PCT/US2012/057053 patent/WO2013052311A1/en not_active Ceased
- 2012-09-25 AP AP2014007532A patent/AP2014007532A0/xx unknown
- 2012-09-25 AU AU2012318956A patent/AU2012318956A1/en not_active Abandoned
- 2012-09-25 KR KR1020147008644A patent/KR20140059271A/ko not_active Withdrawn
- 2012-09-25 CN CN201280048530.2A patent/CN103906530B/zh not_active Expired - Fee Related
-
2013
- 2013-08-13 US US13/965,243 patent/US8883726B2/en active Active
-
2014
- 2014-01-30 IL IL230754A patent/IL230754A0/en unknown
- 2014-02-05 ZA ZA2014/00882A patent/ZA201400882B/en unknown
- 2014-03-06 TN TNP2014000096A patent/TN2014000096A1/en unknown
- 2014-03-06 DO DO2014000050A patent/DOP2014000050A/es unknown
- 2014-03-17 CO CO14057034A patent/CO6910165A2/es unknown
- 2014-03-27 MA MA36861A patent/MA35458B1/fr unknown
- 2014-03-27 CR CR20140142A patent/CR20140142A/es unknown
- 2014-04-02 CL CL2014000801A patent/CL2014000801A1/es unknown
- 2014-04-04 EC ECSP14013285 patent/ECSP14013285A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014530220A5 (OSRAM) | ||
| JP2012041342A5 (OSRAM) | ||
| JP2012532874A5 (OSRAM) | ||
| JP2013155188A5 (OSRAM) | ||
| FI3494972T3 (fi) | Dolutegraviirin ja lamivudiinin yhdistelmiä hiv-infektion hoitoon | |
| JP2013520405A5 (OSRAM) | ||
| EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
| JP2012193216A5 (OSRAM) | ||
| EA201490521A1 (ru) | Варианты фактора роста фибробластов 21 | |
| HRP20161379T1 (hr) | Inhibitori hepatitis c virusa | |
| JP2013541583A5 (OSRAM) | ||
| JP2015517488A5 (OSRAM) | ||
| IL229199A (en) | N– (2– {2– dimethylaminoethyl-methylamino} –4 – methoxy-5 - {[4– (1-methylindol-3-yl) pyrimidine-2-yl] amino} phenyl) prop-2-anamide and salts acceptable in pharmacy Her, pharmaceuticals that include her and its use in the manufacture of cancer drugs | |
| MX2010005631A (es) | Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades. | |
| JP2017532343A5 (OSRAM) | ||
| NZ608502A (en) | Polypeptides that bind to human complement component c5 | |
| JP2014167010A5 (OSRAM) | ||
| EA201490378A1 (ru) | ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β | |
| UA107578C2 (uk) | Комбінована терапія при лікуванні діабету | |
| EA201492010A1 (ru) | Применение высокой дозы лахинимода для лечения рассеянного склероза | |
| EA032938B1 (ru) | Производное глутаримидов, его применение, фармацевтическая композиция на его основе, способ его получения | |
| JP2011528897A5 (OSRAM) | ||
| JP2014532722A5 (OSRAM) | ||
| JP2015516419A5 (OSRAM) | ||
| RU2017145271A (ru) | Терапевтическое средство для фиброза |